대한뉴팜

Daehan New Pharm Co., Ltd. has newly launched the OTC packaging of Sancotec Tablet, a second-generation antihistamine tablet. The Sancotec Tablet (10T) is available for purchase at pharmacies and contains cetirizine hydrochloride, a widely used anti-allergic agent worldwide. It works by blocking histamine receptors and is highly effective for symptoms such as allergic rhinitis, allergic conjunctivitis, urticaria, and itching of the skin. The drug is rapidly absorbed for quick onset of effect and provides 24-hour efficacy with a simple once-daily one-tablet dose. As a second-generation antihistamine, it significantly reduces side effects like drowsiness and sedation. Itively targets H1 receptors without anticholinergic or antiserotonin effects, making it a safe formulation suitable for children aged 6 and above. For inquiries: Academic Development Department 02-3415-7839

Daehan New Pharm Co., Ltd. held the 21st Regular General Meeting of Shareholders on the 18th at the Hyangnam Pharmaceutical Complex in Hyangnam-myeon, Hwaseong-si, Gyeonggi-do. At the meeting, a cash dividend of 50 KRW (10%) was approved. Additionally, attorney Cho Yeon-ho was appointed as a new outside director, succeeding Dr. Yang Ji-won, who stepped down due to personal reasons. Daehan New Pharm's sales for 2004 reached 42.182 billion KRW, marking a strong growth of 17.4% compared to the previous year. Operating profit increased by 30.7% to 2.569 billion KRW due to sales growth, and ordinary profit rose by 5.7% to 1.463 billion KRW. However, net income for the year decreased by 8.4% to 904.8 million KRW due to an increase in deferred corporate taxes. CEO Park Myung-rae stated, "Daehan New Pharm will continue to maximize sales performance through continuous new product development and proactive customer-centered sales and marketing activities this year. We will also strengthen the accuracy and speed of operations by stabilizing the ERP system, making this year the first year for preparing to enter the 100 billion KRW sales era."

Daehan New Pharm Co., Ltd. has launched an intensive 18-day residential training program starting on the 26th, following the large-scale recruitment of new employees to strengthen their marketing, sales, and overseas business departments. Around 30 new and experienced employees,ed through document screening and interviews, including candidates for specialized task forces focusing on strategic product development, began the training at the Blue Monte Training Center in Anyang, Gyeonggi Province. The rigorous training schedule runs daily from 8:00 AM to 9:00 PM and covers basic pharmaceutical environment education, product knowledge, academic studies, and sales techniques. CEO Park Myung-rae, in his opening speech, emphasized that the company's future depends on the correct judgment and proactive actions of the new employees and urged them to devote themselves to the training with strong determination to become key players in self-realization and the company's leap to a top-tier organization.

Daehan New Pharm Officially Launches Redesigned Korean and English Company Website (www.dhnp.co.kr) in 2005 The newly revamped website maximizes visual promotional impact with elegant design while providing more detailed content about the company overall. It offers sector-specific health information for visitors, convenient product search features by business unit, an online application system for job applicants to build a talent pool, and an online purchasing system for partners, delivering diverse functionalities. Unique to Daehan New Pharm compared to typical pharmaceutical websites, an internal online café was introduced to activate staff clubs and enhance employee communication. The company has continuously supported employee clubs to promote a healthy corporate culture, and this new online café is expected to foster exchange between HQ and factory staff and contribute to developing a more progressive corporate culture. Additionally, Daehan New Pharm established a semi-SFA (Sales Force Automation) system integrating sales management and sales information sharing. This system allows sales staff to manage their basic sales activities directly online, while managers and executives can simultaneously monitor consolidated information to make decisions, creating a novel concept of an internal intranet. Daehan New Pharm's semi-SFA system achieves low cost and high efficiency in sales management with essential sales management modules tailored for individual sales staff, enabling easier adaptation than traditional complex systems used by other pharmaceutical companies. The remarkable aspect of this website redevelopment is the integration and operation of three online systems. Through this revamp, Daehan New Pharm aims to strengthen proactive online promotion and departmental online businesses, enhance sales capabilities, and realize organizational harmony, actively responding to pharmaceutical market changes for continuous growth. Meanwhile, since 2003, Daehan New Pharm has also operated a marketing website for obesity-related products called Diet Pharm (www.dietpharm.co.kr).

Daehan New Pharm Strengthens Specialization in Obesity Treatment Field Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) kicked off 2005 with the launch of new products including Fastin Tablet for obesity treatment and iCool Capsules for eye nutrition. At the New Year ceremony held at the Suwon Lavidol Resort with all employees in attendance, the company committed to achieving its sales goals for the year and making 2005 a year of corporate growth. Fastin Tablet contain phentermine hydrochloride, a drug approved by the US FDA for appetite suppression in patients with exogenous obesity. Daehan New Pharm has actively marketed a diverse portfolio of products in the fields of appetite suppressants, fat absorption inhibitors, thermogenesis promoters, and obesity treatment mesotherapy formulations. The launch of Fastin Tablet, expected to capture a significant market, is aimed at cementing the company’s position as a specialist pharmaceutical company in obesity treatment. The obesity treatment market was valued at approximately 50 billion KRW in 2004, and Daehan New Pharm anticipates capturing at least 15% of this market. Recognizing that many clinics show great interest in treating obesity patients but lack familiarity with patient engagement methods, the company plans to train obesity specialist coordinators and develop customer-centric marketing strategies.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has newly launched 'Spo-K Plaster,' an arthritis and muscle pain treatment containing menthol, thereby entering the patch market. Each patch contains 30 mg of ketoprofen and features an added L-menthol component, providing a cooling sensation immediately upon application. Spo-K uses a non-irritating breathable nonwoven fabric, making it safe for patients with sensitive skin, and its enhanced adhesive technology ensures it adheres well to curved areas such as the knees and elbows. The innovative adhesive technology improves adhesion and significantly reduces the problem of edges curling, common in conventional products. Utilizing advanced Transdermal Drug Delivery System (TDDS) technology, the product targets pain areas directly, avoiding systemic side effects like liver toxicity and gastrointestinal disorders associated with oral administration. The current anti-inflammatory and analgesic patch market is dominated by Ketotop Plaster from Taepyeongyang Pharmaceutical and Kephentek Plaster from Jeil Pharmaceutical, forming approximately a 45 billion KRW market in 2005. Daehan New Pharm's new entry with Spo-K Plaster is expected to actively seek expansion in this market. Through this launch, Daehan New Pharm aims to revitalize the stagnating OTC market with diverse marketing strategies, enhance consumer recognition, and strengthen pharmacy sales. The company plans to balance herbal medicines and Western OTC products as part of their product strategy, using this opportunity as a springboard for invigorating pharmacy operations.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held a celebration ceremony at its headquarters auditorium on October 19, marking its 20th anniversary. The event was attended by employees and executives who reaffirmed their commitment to transforming into a total healthcare group. The ceremony featured introductions to the company’s history, awards for long-term employees and outstanding workers, a ceremonial rice cake cutting, and commemorative speeches. Chairman Lee Wan-jin expressed gratitude to all partner companies and customers who have supported Daehan New Pharm with mutual trust and emphasized the importance of understanding the essence of the pharmaceutical industry to sustain the company’s longevity. He urged management to focus on nurturing talent and fulfilling the company’s role in contributing to the advancement of public health. Founded in 1984, Daehan New Pharm began with the production of veterinary medicines and has since expanded to establish state-of-the-art manufacturing facilities in the Hyangnam pharmaceutical complex. The company has built large-scale production lines for various pharmaceutical formulations, including traditional Korean herbal granules, as well as facilities and business units for health foods, beverages, and baby products, steadily progressing toward becoming a total healthcare group. During the ceremony, long-term service awards for 10 years of dedicated service were presented to Assistant Manager Lim Hee-taek and Assistant Manager Kim Seung-hwan from the veterinary production department.

Daehan New Pharm (CEO Park Myung-rae) held the “2004 Mountain March Competition” on the 4th to establish a sense of purpose and strengthen the sales organization. The event took place on a 60km mountain march course from Yanggu, Gangwon Province, to Inje and Hyeon-ri, with about 130 participants from the sales and sales support departments, including CEO Park. The march, which started at midnight after a sales meeting on the 3rd, was conducted along National Road 31, crossing the now-closed old Gwangchiryung Pass to reach Inje and Hyeon-ri. This route, known as the “hell march course,” typically takes about 15 hours and is known to be challenging even for frontline soldiers. The march was organized by small sales teams that encouraged and pushed each other, and all participants completed the march without anyoneping out in about 15 hours. Notably, three female employees voluntarily participated and completed the march alongside their male colleagues. Participant Lee Chae-il (36), team leader of the Ulsan team, said, “Remembering the spirit of my military service 10 years ago, I reflected on my somewhat lax attitude so far and had a good experience strengthening camaraderie with colleagues who sweat together in the sales field. Based on this spirit and organizational strength, I will do my best to achieve the given targets." Since its listing on KOSDAQ, Daehan New Pharm has been solidifying its sales foundation through sound growth, securing excellent talents, and intensive training. The company plans to continue developing similar mental education programs to maintain organizational strength.

Daehan New Pharm obtained the license for 'Health Functional Food Specialized Manufacturing Business' on August 23, 2004.